# Umibio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/umibio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.umibio.cn
- Latest round: Angel (Jul 22, 2022)
- Investors on record: 2

## About

Established in 2016 and based in Shanghai, China, Umibio is a pharmaceutical company focuses on product research and service development in the direction of gene editing and exosome testing. The company has more than 30 software titles under license. In July 2022, the company raised an undisclosed amount angel funding led by new investor Linear Venture.

The company's main business is gene editing and exosome detection direction of product research and service development. The company's self-developed exosome products such as engineered exosomes, 293T exosomes, milk exosome extracts, and exosome-specific media.

## Funding rounds

- Angel, Jul 22, 2022 — Linear Capital, SND Group

## Investors

- Linear Capital (https://capitalatlas.ai/funds/linear-capital) — Angel
- SND Group — Angel